Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals Inc. develops and commercializes biotechnology medicines for serious diseases across eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disease, neurological disease, hematologic conditions, infectious disease and rare disease. News about REGN commonly covers marketed products and pipeline programs such as EYLEA, EYLEA HD, Dupixent, Praluent, Libtayo, Kevzara, Otarmeni and investigational therapies developed through antibody, genetic medicine and RNA-based approaches.
Recurring company updates include financial results, FDA and European regulatory approvals, clinical trial data, label expansions, collaboration and licensing activity, product-access and pricing arrangements, share repurchase authorizations and corporate responsibility recognition. Regeneron's disclosures also frequently address its Sanofi collaboration around Dupixent and its use of proprietary technologies such as VelocImmune in drug discovery.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Regeneron Pharmaceuticals (Nasdaq: REGN) and Alnylam Pharmaceuticals (Nasdaq: ALNY) announced positive interim results from the Phase 1 clinical study of ALN-APP, an RNAi therapeutic targeting amyloid precursor protein for Alzheimer’s disease and cerebral amyloid angiopathy. The study enrolled 20 patients, revealing that single doses of ALN-APP achieved dose-dependent reductions of soluble APPα and APPβ in cerebrospinal fluid, with decreases of up to 90%. Safety and tolerability were encouraging, with only mild to moderate adverse events reported. This marks the first demonstration of RNAi gene silencing in the human brain, utilizing Alnylam's C16 platform. Further data will be disclosed at an upcoming scientific conference, and the trial continues to explore longer-term effects.
On April 17, 2023, Regeneron Pharmaceuticals (NASDAQ: REGN) announced significant leadership changes. P. Roy Vagelos, M.D., the Chair of the Board since 1995, will retire and not seek reelection at the 2023 Annual Meeting on June 9. Following his departure, Leonard S. Schleifer, M.D., Ph.D., and George D. Yancopoulos, M.D., Ph.D., will serve as Co-Chairs of the Board while maintaining their executive roles. Additionally, Christine A. Poon will become the Lead Independent Director. Dr. Vagelos expressed pride in Regeneron's transformation into a leading biopharmaceutical company, confident in the new leadership's ability to enhance shareholder value.